MiMedx Group, Inc. (NASDAQ:MDXG) Insider Kimberly Maersk-Moller Sells 4,106 Shares

MiMedx Group, Inc. (NASDAQ:MDXG) insider Kimberly Maersk-Moller sold 4,106 shares of the stock in a transaction dated Thursday, March 13th. The shares were sold at an average price of $7.89, for a total value of $32,396.34. Following the completion of the transaction, the insider now owns 310,836 shares of the company’s stock, valued at $2,452,496.04. This represents a 1.30 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link.

Kimberly Maersk-Moller also recently made the following trade(s):

• On Friday, February 28th, Kimberly Maersk-Moller sold 2,111 shares of MiMedx Group stock. The stock was sold at an average price of $8.40, for a total value of $17,732.40.

MiMedx Group Trading Up 0.4 %

Shares of MDXG stock opened at $7.92 on Friday. The company has a market cap of $1.17 billion, a P/E ratio of 14.40 and a beta of 1.97. The stock has a 50 day simple moving average of $8.45 and a two-hundred day simple moving average of $7.82. The company has a debt-to-equity ratio of 0.10, a quick ratio of 3.53 and a current ratio of 4.10. MiMedx Group, Inc. has a fifty-two week low of $5.47 and a fifty-two week high of $10.14.

MiMedx Group (NASDAQ:MDXG) last announced its quarterly earnings data on Wednesday, February 26th. The company reported $0.07 EPS for the quarter, meeting analysts’ consensus estimates of $0.07. MiMedx Group had a return on equity of 26.21% and a net margin of 23.86%. The firm had revenue of $92.91 million during the quarter, compared to analysts’ expectations of $89.42 million. Research analysts forecast that MiMedx Group, Inc. will post 0.3 earnings per share for the current year.

Institutional Investors Weigh In On MiMedx Group

A number of hedge funds have recently added to or reduced their stakes in MDXG. Principal Financial Group Inc. grew its stake in MiMedx Group by 6.3% in the third quarter. Principal Financial Group Inc. now owns 55,495 shares of the company’s stock valued at $328,000 after acquiring an additional 3,292 shares during the period. Entropy Technologies LP acquired a new stake in MiMedx Group in the third quarter valued at approximately $64,000. Aigen Investment Management LP acquired a new stake in MiMedx Group in the third quarter valued at approximately $83,000. Victory Capital Management Inc. grew its stake in MiMedx Group by 2.8% in the third quarter. Victory Capital Management Inc. now owns 142,350 shares of the company’s stock valued at $841,000 after acquiring an additional 3,901 shares during the period. Finally, Royce & Associates LP grew its stake in MiMedx Group by 5.3% in the third quarter. Royce & Associates LP now owns 972,853 shares of the company’s stock valued at $5,750,000 after acquiring an additional 48,539 shares during the period. Institutional investors and hedge funds own 79.15% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, Cantor Fitzgerald restated an “overweight” rating and set a $13.00 price objective on shares of MiMedx Group in a research report on Thursday, February 27th.

About MiMedx Group

MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue’s inherent biological properties and regulatory proteins.